Tebipenem is a carbenapenem antibiotic.1,2 It is active against a panel of clinical isolates from a variety of bacterial species (MIC50s = ≤0.0039-8 µg/ml), including methicillin-resistant strains of S. aureus and S. epidermidis and penicillin-resistant S. pneumoniae.1 Tebipenem inhibits β-lactamase in a concentration-dependent manner.2 It decreases the number of colony forming units (CFUs) in the lungs in a mouse model of penicillin-resistant S. pneumoniae infection when administered at doses ranging from 0.32 to 3.2 mg/kg.1
1.Fujimoto, K., Takemoto, K., Hatano, K., et al.Novel carbapenem antibiotics for parenteral and oral applications: In vitro and in vivo activities of 2-aryl carbapenems and their pharmacokinetics in laboratory animalsAntimicrob. Agents Chemother.57(2)697-707(2013) 2.Hazra, S., Xu, H., and Blanchard, J.S.Tebipenem, a new carbapenem antibiotic, is a slow substrate that inhibits the β-lactamase from Mycobacterium tuberculosisBiochemistry53(22)3671-3678(2014)